Warren R P, Morrey J D, Burger R A, Okleberry K M, Sidwell R W
AIDS Research Program, Utah State University, Logan 84322-6895.
Antiviral Res. 1992 Sep;19(3):233-45. doi: 10.1016/0166-3542(92)90082-g.
(B10.A x A/WySn)F1 mice, infected with the Friend virus (FV) complex, were used as a predictive therapeutic model for AIDS. These infected mice exhibit many of the viral and immunologic manifestations of AIDS. Bropirimine (2-amino-5-bromo-6-phenyl-4[3H]pyrimidinone, ABPP) is an immunomodulating compound which has been shown to inhibit other viral infections. Oral (per os treatment) dosages of ABPP ranging from 50 to 400 mg/kg/day for 3 days resulted in increased numbers of infectious centers in the infected mice and increased splenomegaly and percentage of Ig+ (B cells) in spleens of infected and uninfected mice. Decreased percentages of total Thy-1.2+ (total T) cells and L3T4+ (T-helper) cells were seen in both uninfected and infected mice and a slightly decreased percentage of Ly-2+ (T-suppressor/cytotoxic) cells was observed in spleens of the infected mice. No effect on Ly2+ cells in spleens of uninfected mice was found. Intraperitoneal injection, single or multiple, of 20-200 mg/kg ABPP prior to FV injection resulted in increased spleen weights but had no effect on numbers of infectious centers in the spleens or on FV antibody titers in the plasma. Intraperitoneal treatment of uninfected mice with ABPP resulted in slight or no changes in percentages of Thy-1.2+, L3T4+ and Ly-2+ cells. Mice receiving multiple exposures of ABPP had an increase in percentage of splenic B cells and a depressed response to the T cell mitogen PHA. Treatment with ABPP induced the production of interferon (IFN); however, a state of hyporesponsive IFN production was seen following multiple administrations of ABPP. These data suggest that the immunomodulator ABPP may have an enhancing effect on this retroviral disease.
将感染了弗氏病毒（FV）复合体的（B10.A×A/WySn）F1小鼠用作艾滋病的预测性治疗模型。这些受感染的小鼠表现出许多艾滋病的病毒和免疫学表现。布罗匹明（2-氨基-5-溴-6-苯基-4[3H]嘧啶酮，ABPP）是一种免疫调节化合物，已被证明能抑制其他病毒感染。口服（经口给药）ABPP剂量为50至400毫克/千克/天，持续3天，导致受感染小鼠的感染中心数量增加，脾脏肿大加剧，且受感染和未受感染小鼠脾脏中Ig+（B细胞）百分比增加。在未感染和受感染小鼠中均观察到总Thy-1.2+（总T细胞）和L3T4+（辅助性T细胞）细胞百分比降低，在受感染小鼠脾脏中观察到Ly-2+（抑制性/细胞毒性T细胞）细胞百分比略有降低。未发现对未感染小鼠脾脏中的Ly2+细胞有影响。在注射FV之前，单次或多次腹腔注射20 - 200毫克/千克ABPP会导致脾脏重量增加，但对脾脏中的感染中心数量或血浆中的FV抗体滴度没有影响。用ABPP对未感染小鼠进行腹腔治疗，导致Thy-1.2+、L3T4+和Ly-2+细胞百分比略有变化或无变化。多次接触ABPP的小鼠脾脏B细胞百分比增加，对T细胞有丝分裂原PHA的反应降低。用ABPP治疗可诱导干扰素（IFN）的产生；然而，多次给予ABPP后会出现IFN产生反应低下的状态。这些数据表明免疫调节剂ABPP可能对这种逆转录病毒疾病有增强作用。
